AU3182999A - Methods of diagnosis and triage using cell activation measures - Google Patents

Methods of diagnosis and triage using cell activation measures

Info

Publication number
AU3182999A
AU3182999A AU31829/99A AU3182999A AU3182999A AU 3182999 A AU3182999 A AU 3182999A AU 31829/99 A AU31829/99 A AU 31829/99A AU 3182999 A AU3182999 A AU 3182999A AU 3182999 A AU3182999 A AU 3182999A
Authority
AU
Australia
Prior art keywords
triage
diagnosis
methods
cell activation
activation measures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31829/99A
Inventor
Tony E Hugli
Erik Kistler
Geert W. Schmid-Schonbein
Roland B. Stoughton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Scripps Research Institute
Cell Activation Inc
Original Assignee
University of California
Scripps Research Institute
Cell Activation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Scripps Research Institute, Cell Activation Inc filed Critical University of California
Publication of AU3182999A publication Critical patent/AU3182999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
AU31829/99A 1998-03-11 1999-03-11 Methods of diagnosis and triage using cell activation measures Abandoned AU3182999A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/038,894 US20030190368A1 (en) 1998-03-11 1998-03-11 Methods of diagnosis and triage using cell activation measures
US09038894 1998-03-11
PCT/US1999/005247 WO1999046367A2 (en) 1998-03-11 1999-03-11 Methods of diagnosis and triage using cell activation measures

Publications (1)

Publication Number Publication Date
AU3182999A true AU3182999A (en) 1999-09-27

Family

ID=21902511

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31829/99A Abandoned AU3182999A (en) 1998-03-11 1999-03-11 Methods of diagnosis and triage using cell activation measures

Country Status (6)

Country Link
US (1) US20030190368A1 (en)
EP (1) EP1062323A2 (en)
JP (1) JP2002505874A (en)
AU (1) AU3182999A (en)
CA (1) CA2322618A1 (en)
WO (1) WO1999046367A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4676608B2 (en) * 1999-12-21 2011-04-27 武田薬品工業株式会社 Novel tahikinin-like polypeptide and uses thereof
AU2399601A (en) 1999-12-21 2001-07-03 Takeda Chemical Industries Ltd. Novel tachykinin-like polypeptides and use thereof
DE60323091D1 (en) 2002-05-13 2008-10-02 Arexis Ab AUTOIMMUNE DISEASES AND NADPH OXIDASE DEFECTS
JP2006348024A (en) * 2005-05-17 2006-12-28 Santen Pharmaceut Co Ltd Neurocyte-protecting agent comprising amidino derivative as effective ingredient
EP2143431A1 (en) * 2005-05-17 2010-01-13 Santen Pharmaceutical Co., Ltd. Protective agent for neurocyte comprising amidino derivative as active ingredient
JP2006348023A (en) * 2005-05-17 2006-12-28 Santen Pharmaceut Co Ltd Vascularization inhibitor comprising amine derivative as effective ingredient
ES2361932T3 (en) * 2005-05-17 2011-06-24 Santen Pharmaceutical Co., Ltd. ANGIOGENESIS INHIBITOR CONTAINING AN AMINA DERIVATIVE AS ACTIVE INGREDIENT.
WO2007013945A2 (en) * 2005-07-20 2007-02-01 The Regents Of The University Of California Treating disorders associated with inflammation
CA2646293C (en) * 2006-03-15 2015-08-25 The General Hospital Corporation Devices and methods for detecting cells and other analytes
JP5448317B2 (en) * 2007-09-12 2014-03-19 デンカ生研株式会社 Method for reducing measurement error due to catalase inhibition by azide
WO2010087874A1 (en) * 2009-01-28 2010-08-05 Anazyme, Llc Compositions and methods for diagnosis of shock
US8338127B2 (en) * 2008-01-31 2012-12-25 Anazyme Testing a mammal for presence, progression or stage of a shock condition
ES2945032T3 (en) 2010-05-06 2023-06-28 Charm Sciences Inc Incubator device with reader
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
JP6509112B2 (en) * 2012-07-03 2019-05-08 プラブダ，ジェイ Methods for the treatment, diagnosis and / or monitoring of the progression of oxo related conditions
US20150276613A1 (en) * 2012-10-25 2015-10-01 Chrm Sciences, Inc. Definitive development diagnostic analysis
CA3085079A1 (en) 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
CN105492460A (en) 2013-06-14 2016-04-13 哈佛大学的校长及成员们 Stabilized polypeptide insulin receptor modulators
US10226566B2 (en) * 2014-04-23 2019-03-12 Genadyne Biotechnologies, Inc. System and process for removing bodily fluids from a body opening
CA2949535C (en) * 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019084186A1 (en) * 2017-10-24 2019-05-02 Leading BioSciences, Inc. Compositions and methods for glucose control
CN110715842A (en) * 2019-11-15 2020-01-21 河北医科大学第三医院 Use of D-PAS staining related reagent in diagnosis of liver injury
CN111579763B (en) * 2020-04-09 2023-04-07 北京博瑞世安科技有限公司 Method for detecting respiratory function of leucocyte mitochondria and method for detecting kidney yin deficiency
CN117825673B (en) * 2024-03-04 2024-05-10 迈赛凯尔(山东)生命科学有限公司 Exosome detection device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
US5447957A (en) * 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds
US5917013A (en) * 1995-12-06 1999-06-29 Simon W. Rabkin Peptides and their use to ameliorate cell death
WO1999015891A1 (en) * 1997-09-25 1999-04-01 The Regents Of The University Of California System and method for measuring hydrogen peroxide levels in a fluid and method for assessing oxidative stress

Also Published As

Publication number Publication date
CA2322618A1 (en) 1999-09-16
WO1999046367A8 (en) 2000-01-13
WO1999046367A3 (en) 1999-12-09
US20030190368A1 (en) 2003-10-09
EP1062323A2 (en) 2000-12-27
WO1999046367A2 (en) 1999-09-16
JP2002505874A (en) 2002-02-26

Similar Documents

Publication Publication Date Title
AU3182999A (en) Methods of diagnosis and triage using cell activation measures
AU6409799A (en) Tissue analysis and kits therefor
AU7612196A (en) Functional human hematopoietic cells
AU4543099A (en) Sandwich arrays and methods of making and using the same
AU2569599A (en) Cells or tissues with increased protein factors and methods of making and using same
AU3908697A (en) Anodizing electrolyte and its use
AU7362998A (en) Solid state electrochemical sensors and methods of making the same
AU5234698A (en) An ultrasound system and methods utilizing same
AU6763898A (en) Gel sensors and methods of use thereof
AU5301598A (en) Detection of analytes using electrochemistry
AU7713598A (en) Skin pricker
AU5482599A (en) Human mesencephalon cell lines and methods of use therefor
AU2361695A (en) Red blood cell surrogate
AU4998600A (en) Airway-based cardiac output monitor and methods for using same
AU6184396A (en) Solid oral diagnostic test meal and methods of use thereof
AU2871899A (en) Human receptor proteins; related reagents and methods
AU9301998A (en) Composition and methods using galectin-1
AU5923998A (en) 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
AU2087799A (en) Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
AU4202699A (en) Human socs proteins
AU2667197A (en) Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
AU6491699A (en) Biosensor cell device and its use
AU4150999A (en) Method and kit for early diagnosis of cancer
AU1524095A (en) Ex vivo activation of immune cells
AU4565697A (en) Analysis of carbohydrates